Doxorubicin and Cyclophosphamide Plus Paclitaxel With or Without Trastuzumab in Treating Women With Node-Positive Breast Cancer That Overexpresses HER2
Completed
RATIONALE: Drugs used in chemotherapy, such as doxorubicin, cyclophosphamide, and paclitaxel, use different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies such as trastuzumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. It is not yet known whether combination chemotherapy plus trastuzumab is more effective than combination chemotherapy alone for treating breast cancer. PURPOSE: Th... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
04/28/2021
Locations: CCOP - Duluth, Duluth, Minnesota +2 locations
Conditions: Breast Cancer
Calaspargase Pegol or Pegaspargase and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia
Completed
This randomized clinical trial is studying giving calaspargase pegol together with combination chemotherapy to see how well it works compared with giving pegaspargase together with combination chemotherapy in treating younger patients with newly diagnosed high-risk acute lymphoblastic leukemia. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) ma... Read More
Gender:
ALL
Ages:
Between 2 years and 30 years
Trial Updated:
04/02/2021
Locations: Children's Hospitals and Clinics of Minnesota - Minneapolis, Minneapolis, Minnesota +1 locations
Conditions: Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia, Childhood B Acute Lymphoblastic Leukemia
Dexamethasone Compared With Prednisone During Induction Therapy and Methotrexate With or Without Leucovorin During Maintenance Therapy in Treating Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia
Completed
This randomized phase III trial is studying dexamethasone to see how well it works compared to prednisone during induction therapy. This trial is also studying methotrexate and leucovorin calcium to see how well they work compared to methotrexate alone during maintenance therapy in treating patients with newly diagnosed acute lymphoblastic leukemia (ALL). Drugs used in chemotherapy, such as dexamethasone, prednisone, methotrexate, and leucovorin calcium, work in different ways to stop cancer cel... Read More
Gender:
ALL
Ages:
Between 1 year and 30 years
Trial Updated:
04/02/2021
Locations: Children's Hospitals and Clinics of Minnesota - Minneapolis, Minneapolis, Minnesota +3 locations
Conditions: Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia, Childhood B Acute Lymphoblastic Leukemia
Busulfan and Cyclophosphamide Followed By ALLO BMT
Terminated
This is a treatment guideline to allow routine clinical data to be collected and maintained in Oncore (clinical database) and the University of Minnesota Blood and Marrow Database as part of the historical database maintained by the department.
Gender:
ALL
Ages:
44 years and below
Trial Updated:
03/17/2021
Locations: Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota
Conditions: Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndrome
Combination Chemotherapy Alone or With Radiation Therapy in Treating Children With Kidney Cancer
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high energy x-rays to damage tumor cells. It is not yet known whether combination chemotherapy alone or combination chemotherapy plus radiation therapy is more effective for childhood kidney cancer. PURPOSE: Phase III trial to compare the effectiveness of combination chemotherapy with or without radiation therapy in treating children who have kidney canc... Read More
Gender:
ALL
Ages:
Between 0 years and 15 years
Trial Updated:
02/23/2021
Locations: St. Mary's/Duluth Clinic Cancer Center, Duluth, Minnesota +3 locations
Conditions: Kidney Cancer
A Study Evaluating Safety and Efficacy of the Addition of ABT-888 Plus Carboplatin Versus the Addition of Carboplatin to Standard Chemotherapy Versus Standard Chemotherapy in Subjects With Early Stage Triple Negative Breast Cancer
Completed
This is a 3 arm Phase 3 study to evaluate the safety and efficacy of the addition of veliparib plus carboplatin versus the addition of carboplatin to standard neoadjuvant chemotherapy versus standard neoadjuvant chemotherapy in subjects with early stage TNBC.
Gender:
FEMALE
Ages:
Between 18 years and 99 years
Trial Updated:
01/15/2021
Locations: Minnesota Oncology Hematology, PA /ID# 126144, Minneapolis, Minnesota
Conditions: Triple Negative Breast Cancer
Stem Cell Transplant for Hematological Malignancy
Terminated
The purpose of this study is to develop a standard of care treatment using allogeneic stem cells for patients with cancers of the blood. The protocol was revised to reflect that this study is considered "treatment guidelines", rather than a research study.
Gender:
ALL
Ages:
55 years and below
Trial Updated:
12/31/2020
Locations: Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota
Conditions: Leukemia, Myeloid, Chronic, AML, Leukemia, Lymphocytic, Acute, MDS, Leukemia, Lymphocytic, Chronic, JMML, Hodgkin's Disease, Non-hodgkin's Lymphoma, Multiple Myeloma
Donor Stem Cell Transplant in Treating Patients With Previously Treated Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia
Completed
RATIONALE: Giving chemotherapy, such as cyclophosphamide and busulfan, and total-body irradiation before a donor stem cell transplant helps stop the growth of cancer cells. It also stops the patient's immune system from rejecting the donor's stem cells. The donated stem cells from bone marrow or umbilical cord blood may replace the patient's immune cells and help destroy any remaining cancer cells (graft-versus-tumor effect). Sometimes the transplanted cells from a donor can also make an immune... Read More
Gender:
ALL
Ages:
55 years and below
Trial Updated:
11/12/2020
Locations: Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota
Conditions: Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
Non-Myeloablative Conditioning for Unrelated Donor Umbilical Cord Blood Transplant
Completed
RATIONALE: Drugs used in chemotherapy, such as fludarabine and cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill cancer cells. An umbilical cord blood transplant may be able to replace blood-forming cells that were destroyed by chemotherapy and radiation therapy. Sometimes the transplanted cells from a donor can make an immune response against the body's nor... Read More
Gender:
ALL
Ages:
75 years and below
Trial Updated:
10/30/2020
Locations: Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota
Conditions: Myeloproliferative Disorders, Leukemia, Lymphoma, Myelodysplastic Syndromes
Combination Chemotherapy With or Without Colony-stimulating Factors in Treating Women With Breast Cancer
Completed
RATIONALE: 1. . To compare the effects on breast cancer of three different combinations of drugs which are commonly used to treat this disease. 2. . It is not yet known which treatment regimen is most effective for breast cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of combination chemotherapy given with or without epoetin alfa in treating women who have undergone surgery for stage I, stage II, or stage III breast cancer.
Gender:
FEMALE
Ages:
60 years and below
Trial Updated:
09/11/2020
Locations: St. Luke's Cancer Care Centre, Duluth, Minnesota +1 locations
Conditions: Breast Cancer
Myeloablative Umbilical Cord Blood Transplantation in Hematological Diseases
Completed
RATIONALE: Giving chemotherapy drugs, such as fludarabine and cyclophosphamide, and total-body irradiation before a donor umbilical cord blood stem cell transplant helps stop the growth of cancer cells and prepares the patient's bone marrow for the stem cells. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. Sometimes the transplanted cells from a donor can make an imm... Read More
Gender:
ALL
Ages:
55 years and below
Trial Updated:
09/09/2020
Locations: Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota
Conditions: Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Chronic Myelogenous Leukemia, Myelofibrosis, MDS, Refractory Anemia, Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia, Non-Hodgkin's Lymphoma, Leukemia, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes
BETH Study: Treatment of HER2 Positive Breast Cancer With Chemotherapy Plus Trastuzumab vs Chemotherapy Plus Trastuzumab Plus Bevacizumab
Terminated
The trial will determine the value of adding bevacizumab to chemotherapy plus trastuzumab in patients with resected node-positive or high risk node-negative, HER2-positive breast cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
09/09/2020
Locations: Minnesota Oncology Hematology-Burnsville, Burnsville, Minnesota +12 locations
Conditions: Breast Cancer